0.35%
6.16%
24.51%
23.27%
34.73%
702.02%
238.83%
AI Spotlight on RYTM
Company Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders.
Rhythm Pharmaceuticals, Inc.has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome.The company was formerly known as Rhythm Metabolic, Inc.
and changed its name to Rhythm Pharmaceuticals, Inc.in October 2015.Rhythm Pharmaceuticals, Inc.
was founded in 2008 and is headquartered in Boston, Massachusetts.
Market Data
| Last Price | 59.43 |
| Change Percentage | 0.35% |
| Open | 59.22 |
| Previous Close | 59.22 |
| Market Cap ( Millions) | 3652 |
| Volume | 402344 |
| Year High | 68.58 |
| Year Low | 35.17 |
| M A 50 | 57.6 |
| M A 200 | 48.85 |
Financial Ratios
| FCF Yield | -3.41% |
| Dividend Yield | 0.00% |
| ROE | -369.26% |
| Debt / Equity | 35.93% |
| Net Debt / EBIDTA | 18.27% |
| Price To Book | 324.41 |
| Price Earnings Ratio | -13.98 |
| Price To FCF | -29.36 |
| Price To sales | 32.46 |
| EV / EBITDA | -15.16 |
News
- Jan -28 - Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet
- Jan -22 - Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?
- Jan -10 - Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
- Dec -20 - Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
- Dec -20 - Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
- Dec -03 - Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
- Nov -18 - Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
- Nov -13 - Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
- Nov -13 - Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Nov -06 - Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
- Nov -06 - Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript
- Nov -05 - Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
- Nov -05 - Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
- Nov -04 - Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
- Oct -29 - Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- Oct -24 - Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
- Oct -08 - Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Sep -22 - Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
- Sep -18 - Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
- Sep -16 - Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Therapeutics
Expected Growth : 25.9 %
What the company do ?
Rhythm Pharmaceuticals' therapeutics focus on peptide therapeutics for rare genetic disorders of obesity and metabolism, including setmelanotide for POMC, PCSK1, and LEPR deficiency.
Why we expect these perspectives ?
Growing prevalence of rare genetic disorders, increasing awareness of peptide therapeutics, and Rhythm's lead candidate setmelanotide's potential to address unmet needs in POMC, PCSK1, and LEPR deficiency drive growth in this segment.
Rhythm Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| Setmelanotide | Setmelanotide is a melanocortin-4 receptor (MC4R) agonist, a novel, first-in-class therapy for the treatment of obesity and rare genetic disorders of obesity. |
| IMCIVREE | IMCIVREE is a melanocortin-4 receptor (MC4R) agonist, a novel, first-in-class therapy for the treatment of obesity and rare genetic disorders of obesity. |
Rhythm Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Rhythm Pharmaceuticals, Inc. operates in the biotechnology industry, which is characterized by high research and development costs. This makes it difficult for substitutes to emerge, reducing the threat of substitutes.
Bargaining Power Of Customers
Rhythm Pharmaceuticals, Inc. primarily sells its products to healthcare providers and patients, who have limited bargaining power due to the specialized nature of the company's products.
Bargaining Power Of Suppliers
Rhythm Pharmaceuticals, Inc. relies on a limited number of suppliers for raw materials and services, which gives them some bargaining power. However, the company's strong relationships with its suppliers mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to enter the market.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Rhythm Pharmaceuticals, Inc. faces intense competition from companies with similar products and pipelines.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.74% |
| Debt Cost | 14.29% |
| Equity Weight | 99.26% |
| Equity Cost | 14.29% |
| WACC | 14.29% |
| Leverage | 0.74% |
Rhythm Pharmaceuticals, Inc. : Quality Control
Rhythm Pharmaceuticals, Inc. passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CLDX | Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with … |
| FOLD | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the … |
| CYTK | Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily … |
| BMRN | BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment … |
| PTCT | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
PTC Therapeutics
A-Score
1-Year Total Return ->
🥈
BioMarin Pharmaceutical
A-Score
1-Year Total Return ->
🥉
Amicus Therapeutics
A-Score
1-Year Total Return ->
4
Rhythm Pharma
A-Score
1-Year Total Return ->
5
Cytokinetics
A-Score
1-Year Total Return ->
6
